Suzuki-Miyaura cross-coupling of heteroaryl halides and arylboronic acids in continuous flow.Org Lett. 2011 Oct 07; 13(19):5180-3.OL
Abstract
General continuous-flow conditions for the Suzuki-Miyaura cross-coupling of heteroaryl halides and (hetero)arylboronic acids have been developed. A wide range of heterobiaryl products is obtained in excellent yields (20 examples) employing low catalyst loadings (0.05-1.5 mol % Pd).
Links
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
21899298
Citation
Noël, Timothy, and Andrew J. Musacchio. "Suzuki-Miyaura Cross-coupling of Heteroaryl Halides and Arylboronic Acids in Continuous Flow." Organic Letters, vol. 13, no. 19, 2011, pp. 5180-3.
Noël T, Musacchio AJ. Suzuki-Miyaura cross-coupling of heteroaryl halides and arylboronic acids in continuous flow. Org Lett. 2011;13(19):5180-3.
Noël, T., & Musacchio, A. J. (2011). Suzuki-Miyaura cross-coupling of heteroaryl halides and arylboronic acids in continuous flow. Organic Letters, 13(19), 5180-3. https://doi.org/10.1021/ol202052q
Noël T, Musacchio AJ. Suzuki-Miyaura Cross-coupling of Heteroaryl Halides and Arylboronic Acids in Continuous Flow. Org Lett. 2011 Oct 7;13(19):5180-3. PubMed PMID: 21899298.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Suzuki-Miyaura cross-coupling of heteroaryl halides and arylboronic acids in continuous flow.
AU - Noël,Timothy,
AU - Musacchio,Andrew J,
Y1 - 2011/09/07/
PY - 2011/9/9/entrez
PY - 2011/9/9/pubmed
PY - 2012/1/18/medline
SP - 5180
EP - 3
JF - Organic letters
JO - Org Lett
VL - 13
IS - 19
N2 - General continuous-flow conditions for the Suzuki-Miyaura cross-coupling of heteroaryl halides and (hetero)arylboronic acids have been developed. A wide range of heterobiaryl products is obtained in excellent yields (20 examples) employing low catalyst loadings (0.05-1.5 mol % Pd).
SN - 1523-7052
UR - https://www.unboundmedicine.com/medline/citation/21899298/Suzuki_Miyaura_cross_coupling_of_heteroaryl_halides_and_arylboronic_acids_in_continuous_flow_
L2 - https://doi.org/10.1021/ol202052q
DB - PRIME
DP - Unbound Medicine
ER -